Lee's Pharmaceutical Holdings Limited's market cap is currently HK$747.82M. The company's EPS TTM is HK$0.107; its P/E ratio is 11.86; and it has a dividend yield of 2.36%. Lee's Pharmaceutical Holdings Limited is scheduled to report earnings on March 27, 2025, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	HK$ 1.05B	HK$ 1.23B	HK$ 1.27B	HK$ 1.22B	HK$ 1.22B
Gross Profit	HK$ 551.31M	HK$ 770.75M	HK$ 806.28M	HK$ 781.07M	HK$ 798.26M
Operating Income	HK$ 36.04M	HK$ 123.02M	HK$ -694.00K	HK$ 151.92M	HK$ 244.60M
EBITDA	HK$ 193.05M	HK$ 229.06M	HK$ 2.13B	HK$ 279.43M	HK$ 235.55M
Net Income	HK$ 16.70M	HK$ 51.28M	HK$ 1.99B	HK$ 78.53M	HK$ 63.34M
Balance Sheet
Cash & Short-Term Investments	HK$ 171.00M	HK$ 189.30M	HK$ 277.53M	HK$ 414.54M	HK$ 775.13M
Total Assets	HK$ 2.89B	HK$ 2.78B	HK$ 3.64B	HK$ 3.25B	HK$ 3.64B
Total Debt	HK$ 204.14M	HK$ 163.49M	HK$ 267.14M	HK$ 156.71M	HK$ 167.94M
Net Debt	HK$ 33.14M	HK$ -25.81M	HK$ -10.39M	HK$ -257.83M	HK$ -607.19M
Total Liabilities	HK$ 930.07M	HK$ 939.50M	HK$ 1.25B	HK$ 1.14B	HK$ 1.16B
Stockholders' Equity	HK$ 2.04B	HK$ 1.92B	HK$ 2.46B	HK$ 2.15B	HK$ 2.30B
Cash Flow
Free Cash Flow	HK$ -45.89M	HK$ 69.81M	HK$ -160.04M	HK$ -139.23M	HK$ 39.38M
Operating Cash Flow	HK$ 110.08M	HK$ 283.63M	HK$ 210.68M	HK$ 218.91M	HK$ 399.95M
Investing Cash Flow	HK$ -145.22M	HK$ -256.05M	HK$ -370.28M	HK$ -523.74M	HK$ -261.41M
Financing Cash Flow	HK$ 13.44M	HK$ -128.60M	HK$ 60.97M	HK$ -9.80M	HK$ 323.79M

Currency in HKD

Lee's Pharmaceutical Holdings Limited Earnings and Revenue History

Income Statement >

Lee's Pharmaceutical Holdings Limited Debt to Assets

Balance Sheet >

Lee's Pharmaceutical Holdings Limited Cash Flow

Cash Flow >

Lee's Pharmaceutical Holdings Limited Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing